# EDGAR Filing Document

**Accession Number:** 0002088432
**File Stem:** 0001213900-25-094430
**Filing Date:** 2025-10
**Character Count:** 7118
**Document Hash:** 1f03c1d46b66d33b8bb81ea4c9a052ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-094430.hdr.sgml**: 20251001

**ACCESSION NUMBER**: 0001213900-25-094430

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250926

**FILED AS OF DATE**: 20251001

**DATE AS OF CHANGE**: 20251001

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II LLC
- **CENTRAL INDEX KEY:** 0002088432

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42863
- **FILM NUMBER:** 251363019

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD, SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3099

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD, SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II Corp.
- **CENTRAL INDEX KEY:** 0002040475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Drugs Made In America Acquisition II LLC<br><sub>(Last) (First) (Middle)</sub><br>1 EAST BROWARD BOULEVARD, SUITE 700<br><sub>(Street)</sub><br>FORT LAUDERDALE, FL 33301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-26 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Drugs Made In America Acquisition II Corp. [ DMII ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary shares | 2025-09-26 |  | P |  | 700000 | A | <sup>(1)</sup> | 15075000 | D |  |
| Ordinary shares | 2025-09-26 |  | J<sup>(2)</sup> |  | 400000 | D | <sup>(2)</sup> | 14675000 | D |  |
| Ordinary shares | 2025-09-26 |  | S |  | 7966667 | D | <sup>(3)</sup> | 6708333 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Rights to receive ordinary shares | <sup>(4)</sup> | 2025-09-26 |  | P |  | 700000 |  | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary shares | 700000 | <sup>(1)(4)</sup> | 700000 | D |  |

---

### Footnotes:

(1) Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000.

(2) As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.

(3) As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.

(4) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.

**Signature:** /s/ / Lynn Stockwell as managing member  
**Date:** 2025-10-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**